APA

Desroy N., Housseman C., Bock X., Joncour A., Bienvenu N., Cherel L., Labeguere V., Rondet E., Peixoto C., Grassot J., Picolet O., Annoot D., Triballeau N., Monjardet A., Wakselman E., Roncoroni V., Le Tallec S., Blanque R., Cottereaux C., Vandervoort N., Christophe T., Mollat P., Lamers M., Auberval M., Hrvacic B., Ralic J., Oste L., van der Aar E., Brys R. & Heckmann B. (20170711). Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. : Journal of medicinal chemistry.

Chicago

Desroy Nicolas, Housseman Christopher, Bock Xavier, Joncour Agnès, Bienvenu Natacha, Cherel Laëtitia, Labeguere Virginie, Rondet Emilie, Peixoto Christophe, Grassot Jean-Marie, Picolet Olivier, Annoot Denis, Triballeau Nicolas, Monjardet Alain, Wakselman Emanuelle, Roncoroni Veronique, Le Tallec Sandrine, Blanque Roland, Cottereaux Celine, Vandervoort Nele, Christophe Thierry, Mollat Patrick, Lamers Marieke, Auberval Marielle, Hrvacic Boska, Ralic Jovica, Oste Line, van der Aar Ellen, Brys Reginald and Heckmann Bertrand. 20170711. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. : Journal of medicinal chemistry.

Harvard

Desroy N., Housseman C., Bock X., Joncour A., Bienvenu N., Cherel L., Labeguere V., Rondet E., Peixoto C., Grassot J., Picolet O., Annoot D., Triballeau N., Monjardet A., Wakselman E., Roncoroni V., Le Tallec S., Blanque R., Cottereaux C., Vandervoort N., Christophe T., Mollat P., Lamers M., Auberval M., Hrvacic B., Ralic J., Oste L., van der Aar E., Brys R. and Heckmann B. (20170711). Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. : Journal of medicinal chemistry.

MLA

Desroy Nicolas, Housseman Christopher, Bock Xavier, Joncour Agnès, Bienvenu Natacha, Cherel Laëtitia, Labeguere Virginie, Rondet Emilie, Peixoto Christophe, Grassot Jean-Marie, Picolet Olivier, Annoot Denis, Triballeau Nicolas, Monjardet Alain, Wakselman Emanuelle, Roncoroni Veronique, Le Tallec Sandrine, Blanque Roland, Cottereaux Celine, Vandervoort Nele, Christophe Thierry, Mollat Patrick, Lamers Marieke, Auberval Marielle, Hrvacic Boska, Ralic Jovica, Oste Line, van der Aar Ellen, Brys Reginald and Heckmann Bertrand. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. : Journal of medicinal chemistry. 20170711.